- Home
- RDHL vs SNTI Comparison
RDHL vs SNTI Comparison
Compare RDHL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- SNTI
- Stock Information
- Founded
- RDHL 2009
- SNTI 2016
- Country
- RDHL Israel
- SNTI United States
- Employees
- RDHL N/A
- SNTI N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- SNTI Health Care
- Exchange
- RDHL Nasdaq
- SNTI Nasdaq
- Market Cap
- RDHL 11.2M
- SNTI 10.4M
- IPO Year
- RDHL N/A
- SNTI N/A
- Fundamental
- Price
- RDHL $7.08
- SNTI $2.23
- Analyst Decision
- RDHL
- SNTI
- Analyst Count
- RDHL 0
- SNTI 0
- Target Price
- RDHL N/A
- SNTI N/A
- AVG Volume (30 Days)
- RDHL 14.3K
- SNTI 16.0K
- Earning Date
- RDHL 11-19-2024
- SNTI 11-26-2024
- Dividend Yield
- RDHL N/A
- SNTI N/A
- EPS Growth
- RDHL N/A
- SNTI N/A
- EPS
- RDHL N/A
- SNTI N/A
- Revenue
- RDHL $3,707,000.00
- SNTI $338,000.00
- Revenue This Year
- RDHL $224.90
- SNTI $254.47
- Revenue Next Year
- RDHL $82.69
- SNTI $169.66
- P/E Ratio
- RDHL N/A
- SNTI N/A
- Revenue Growth
- RDHL N/A
- SNTI N/A
- 52 Week Low
- RDHL $6.80
- SNTI $1.52
- 52 Week High
- RDHL $82.00
- SNTI $7.43
- Technical
- Relative Strength Index (RSI)
- RDHL 29.71
- SNTI 49.58
- Support Level
- RDHL $7.98
- SNTI $2.12
- Resistance Level
- RDHL $7.36
- SNTI $2.32
- Average True Range (ATR)
- RDHL 0.37
- SNTI 0.15
- MACD
- RDHL -0.12
- SNTI 0.02
- Stochastic Oscillator
- RDHL 0.00
- SNTI 43.18
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.